Altrenogest (INN, USAN, BAN) (brand name Regumate), also known as allyltrenbolone, is a steroidal progestin that is widely used in veterinary medicine to suppress estrus in animals. Altrenogest is an orally active progestin developed for use in the horse. Altrenogest has been chemically modified by addition of a hydroxyl group and 3 carbon chain placed on carbon 17 of the progestin. Research has demonstrated that Altrenogest has low anabolic activity and is 20 times less potent than testosterone or similar progestins when compared for effects on muscle growth in castrated rats

Betadex is a nonreducing cyclic compound composed of seven alpha-(1-4) linked D-glucopyranosyl units. It is a pharmacologically inactive substance. Betadex is useful for stabilizing, solubilizing or delivering intermediate size molecules. Cyclodextrins are cyclic oligosaccharides that have been used to modulate the composition of cholesterol and other lipids in biological membranes and have also been used as pharmaceutical excipients in the formulation of hydrophobic drugs. More recently, 2-Hydroxypropyl-β-cyclodextrins (HPβCDs) have gained attention as a potential therapeutic intervention for Niemann-Pick Disease Type C1 (NPC1) disease. HPβCDs are complex mixtures of different species, and variations in production may lead to differences in composition. 2-Hydroxypropyl-β-cyclodextrin dose-dependent effects against dysfunctional intracellular cholesterol trafficking in NPC1 cells.

Beta-Hydroxyisovaleric acid (also known as 3-hydroxyisovaleric acid or 3HIA) is a normal human metabolite excreted in the urine. It is a byproduct of the leucine degradation pathway. Beta-Hydroxyisovaleric acid serves as a sensitive indicator of marginal biotin deficiency in humans. The variability of the proportion of leucine catabolites excreted as 3HIA suggests substantial population heterogeneity in the metabolic capacity of the 3HIA-carnitine detoxification pathway. In addition, was shown that in type II diabetic patients the catabolism of leucine was accelerated even in the absence of ketosis and that the urinary beta-hydroxyisovaleric acid concentration was a useful marker of short-term metabolic control in these patients.

Hexoprenaline is a selective beta2-adrenoreceptor agonist indicated for use in the treatment of bronchospasm associated with obstructive airways diseases, including asthma, bronchitis and emphysema. In many countries the drug is used as tocolytic agent (under the trade name gynipral).

Xamoterol (ICI 118,587) is a partial agonist of beta1-adrenoceptors. Xamoterol acts on the cardiac beta 1-adrenergic receptor, modifies the response of the heart to variations in sympathetic activity. At rest, it produces modest improvements in cardiac contractility, relaxation, and filling without increase in myocardial oxygen demand. The improvements are maintained during exercise although the attendant tachycardia is attenuated. The beneficial effects of xamoterol on both systolic and diastolic function suggested that it would be effective in patients with mild-to-moderate heart failure, and this was demonstrated in small placebo-controlled studies where effort tolerance and symptoms were improved. Xamoterol produced improvements in exercise capacity, clinical signs, symptoms and quality of life with a low incidence of adverse experiences. Xamoterol is effective as monotherapy in heart failure.

Denopamine is a selective agonist of beta-1 adrenergic receptor. The drug was approved in Japan under the name Kalgut for the treatment of chronic heart failure.